Core Viewpoint - Nearly half of the A-share listed companies are expected to report losses for the 2025 fiscal year, with significant regional and industry disparities in the distribution of these losses [2][3]. Group 1: Regional Distribution of Losses - A total of 2,957 A-share companies disclosed their performance forecasts, with 1,442 companies expected to incur losses, representing 49% of the total [3]. - Hainan, Jilin, and Qinghai have the highest proportions of companies forecasting losses, exceeding 40%, with Hainan at 44.44% [4][5]. - Guangdong has the highest number of loss-making companies at 257, followed by Beijing (172), Jiangsu (160), and Zhejiang (133) [4]. Group 2: Industry Analysis - The real estate sector is the most affected, producing the highest number of loss-making companies, including the "loss king" Vanke A, which is expected to report a loss of approximately 82 billion yuan [7][8]. - Other industries with significant losses include IT services, semiconductors, and chemical pharmaceuticals, with 60, 50, and 40-50 companies respectively forecasting losses [7]. - The top ten companies with the highest expected losses include five from the real estate sector, with notable losses from China Fortune Land Development and Greenland Holdings [7][8]. Group 3: Specific Company Losses - Vanke A's losses are attributed to a significant decline in project settlement scale and increased business risks, leading to credit and asset impairment provisions [7]. - Other major loss-makers include China Fortune Land Development, expected to lose between 16 billion to 24 billion yuan, and Greenland Holdings, with losses projected between 16 billion to 19 billion yuan [8]. - In the retail sector, M.K. Home is expected to report losses of 15 billion to 22.5 billion yuan due to investment property valuation losses [8]. - Semiconductor company Wentech Technology anticipates losses of 9 billion to 13.5 billion yuan, primarily due to significant investment losses and asset impairments [9].

Company Dynamics - The chairman of Beijing Dabeinong Technology Group Co., Ltd., Shao Genhuo, passed away on February 3, 2026, at the age of 60, prompting the company to express deep condolences by adjusting its website to a black-and-white interface and displaying his portrait [2] - Shao Genhuo, born in Jinhua, Zhejiang, entered Zhejiang Agricultural University in 1982 and later completed his doctoral studies at China Agricultural University, becoming one of the early agricultural PhDs in China [2] - In 1993, he founded Beijing Dabeinong Feed Technology Co., Ltd. with an initial capital of 20,000 yuan, which later evolved into Dabeinong Group, adhering to the philosophy of "serving the country and promoting agriculture" [2] - Dabeinong has expanded from the feed industry to multiple sectors, including seed industry, animal health, and vaccines, establishing itself as a leading enterprise in China's agricultural technology sector [2] - As of the end of 2024, Dabeinong has developed three core business segments: feed, seed, and pig farming, with feed production capacity exceeding 10 million tons and an annual pig output of 6.4 million heads [2] Management Philosophy and Social Responsibility - Shao Genhuo's management philosophy was forward-looking, exemplified by the employee stock ownership plan launched in 2014, where he distributed 6% of his shares (valued at over 1.3 billion yuan) to 3,000 employees, transitioning the company's governance from a family-based model to a platform-based one [3] - Dabeinong has demonstrated a strong sense of social responsibility, with special scholarships totaling over 45 million yuan benefiting more than 36,000 agricultural university students and faculty [3] - Shao Genhuo ranked high on the Harvard China Charity List, with personal donations totaling 150 million yuan in 2021, including a 10 million yuan donation to Xiamen University, reflecting his commitment to "serving the country and promoting agriculture" [3]

Core Viewpoint - Zhifei Biological has received approval from the National Medical Products Administration for clinical trials of its self-developed lyophilized varicella inactivated vaccine, aimed at preventing varicella caused by varicella-zoster virus infection [1][5]. Group 1: Vaccine Development - The varicella vaccine is designed to prevent varicella, an acute infectious disease caused by the varicella-zoster virus, which poses significant health risks, especially to children and immunocompromised individuals [5]. - The vaccine is considered the most economical and effective method for preventing varicella [5]. Group 2: Company Positioning - Zhifei Biological has a strong presence in vaccine research and development, supported by rigorous scientific approaches, substantial technical accumulation, and continuous R&D investment [5]. - The approval of the varicella vaccine for clinical trials reflects the company's commitment to addressing public health needs and fulfilling social responsibilities [5]. - Successful progress in this project is expected to enhance the company's vaccine portfolio, improve product layout, and strengthen its market position [5].

Core Insights - The performance forecasts for A-share vaccine companies in 2025 reveal significant industry adjustments, with major players like Zhifei Biological, Wantai Biological, and Baike Biological reporting losses, while companies like CanSino and Watson Biologics achieve growth through innovative products and overseas market expansion [1][2][5] Industry Overview - The vaccine industry is facing multiple pressures, including price wars and shrinking demand, leading to a significant contraction in profitability [5][6] - The continuous price competition has compressed profit margins, with HPV vaccines and flu vaccines reaching historical lows in pricing, impacting overall industry profitability [5][6] - The decline in birth rates has reduced the core vaccination population for children's vaccines, while adult vaccine uptake remains low due to vaccine hesitancy [5][6] Company Performance - Zhifei Biological is expected to report its first annual loss since its listing, with a projected net loss of 10.698 billion to 13.726 billion yuan, a year-on-year decline of 630% to 780% [1] - Wantai Biological and Baike Biological also shift from profit to loss, with projected net losses of 330 million to 410 million yuan and 220 million to 280 million yuan, respectively [1] - CanSino is projected to turn a profit with a net income of 24.5 million to 29 million yuan, benefiting from the strong sales of its quadrivalent meningococcal vaccine [2] - Watson Biologics expects a net profit of 160 million to 190 million yuan, driven by a 35% increase in overseas vaccine exports [2] Market Dynamics - The industry is experiencing severe product homogeneity, leading to intensified competition among companies in popular vaccine segments like HPV and shingles [6] - Companies overly reliant on agency models are facing challenges, as seen with Zhifei Biological, which has a high dependency on agency products [6] - Inventory and cash flow pressures are evident, with companies like Zhifei Biological and Wantai Biological facing significant inventory write-downs [6] Innovation and Opportunities - Companies with unique innovative products are achieving performance rebounds, with CanSino's quadrivalent vaccine capturing over 90% market share [7] - The overseas market is becoming a crucial growth point, with Watson Biologics exporting to 24 countries and CanSino's inhaled vaccine gaining market share in Southeast Asia and Latin America [8] - The inclusion of the bivalent HPV vaccine in the national immunization program is expected to stabilize market demand while also compressing profit margins for companies [9] Future Outlook - 2025 is seen as a pivotal year for the vaccine industry to transition towards high-quality development, with a focus on innovation and overseas market expansion [10] - The industry is expected to gradually emerge from the adjustment period as innovative products are launched and vaccination awareness increases among residents [10] - The China Vaccine Industry Association has initiated measures to curb irrational price competition, aiming for a more rational pricing environment in the future [10]

Core Viewpoint - The vaccine industry in A-shares is experiencing significant performance declines in 2025, with major companies like Zhifei Biological, Wantai Biological, and Baike Biological reporting losses, while companies like CanSino and Watson Biologics are achieving growth through innovative products and overseas market expansion [1][4]. Group 1: Industry Performance - Zhifei Biological is expected to report its first annual loss since its listing, with a projected net loss of CNY 10.698 billion to CNY 13.726 billion, a year-on-year decline of 630% to 780% [1]. - Wantai Biological and Baike Biological have also shifted from profit to loss, with Wantai's net loss projected at CNY 330 million to CNY 410 million due to inventory write-downs and pricing pressures [1][3]. - CanSino is projected to turn a profit with a net income of CNY 24.5 million to CNY 29 million, benefiting from the strong sales of its innovative vaccine [4]. Group 2: Market Challenges - The industry is facing multiple pressures, including price wars and reduced demand, leading to significant profit margin compression [6]. - The birth rate decline is reducing the core vaccination population, with the proportion of children aged 0-6 years expected to drop from 64.6% in 2020 to 43.7% in 2024 [6]. - The phenomenon of "vaccine hesitancy" is also impacting adult vaccination rates, with annual flu vaccination rates below 4% [6]. Group 3: Strategic Shifts - Companies are being forced to transition from channel-driven models to innovation-driven strategies due to competitive pressures [6][10]. - The inclusion of the HPV vaccine in the national immunization program is expected to stabilize market demand but will also compress profit margins, pushing companies to innovate and reduce costs [9]. - The industry is witnessing a shift towards overseas markets, with Watson Biologics reporting a 35% increase in vaccine exports, highlighting the potential for growth outside domestic markets [4][8]. Group 4: Future Outlook - The vaccine industry is anticipated to undergo a transformation towards high-quality development in 2025, with a focus on innovation and overseas expansion [9][10]. - The Chinese Vaccine Industry Association has called for a ban on bidding below cost to combat price wars, indicating a move towards more rational competition [10]. - Companies that can innovate and adapt to new market conditions are expected to emerge stronger from the current industry adjustments [10].

"疫苗因为是针对健康人的，它对保护效力的要求极高……这需要我们在创新技术上去深耕。"刘思光强 调，AI技术的引入正在从根本上改变研发效率。 具体而言，吉诺卫生物对于AI的应用体现正在抗原智能设计上，公司通过大数据模型，令AI自动遮盖 抗原表位中的无效部分，并突出有效免疫保护表位。这种"降维打击"式的设计方式，能极大缩短抗原验 证的闭环时间。 而智能化生产线(工业4.0)的引入，使得生产全流程实现智能化控制。据刘思光介绍，以流感疫苗为例， 传统企业的生产周期约为21天，而通过自动化连续作业，该流程可缩短至14天。 在创新药集体"出海"的宏大叙事中，中国药企已然告别了依靠单个明星产品偶然获胜的1.0时代。2025 年中国创新药海外授权总额突破1300亿美元，这股浪潮在2026年开年不仅没有减速，反而进化为以研发 能力和源头创新为核心的价值竞争阶段。 特别是在疫苗行业，过去那种"品种模仿"的思维正在被深度的"范式创新"所取代。中国疫苗企业正尝试 在由辉瑞(Pfizer)、GSK、默沙东(MSD)等跨国巨头长期主导的全球红海市场中，寻找一种新的平衡。 在2026年初举办的亚洲金融论坛上，如何利用人工驱动医疗创新的讨论 ...

Core Viewpoint - The A-share market has seen a significant number of companies disclose their 2025 annual performance forecasts, with approximately 3,000 companies participating, providing crucial insights for market performance predictions. Group 1: Performance Forecasts - A total of 2,956 companies in the Shanghai, Shenzhen, and Beijing stock exchanges disclosed their 2025 performance forecasts, with 705 companies expecting profit increases, 420 companies anticipating profit decreases, and 987 companies projecting continued losses. Additionally, 374 companies expect to turn losses into profits [1] - Ningbo Fubang (SH600768) leads with an expected profit increase of over 30 times, while Vanke A (SZ000002) is projected to incur a loss of 82 billion yuan, marking it as the "loss leader" [1] Group 2: Notable Profit Increases - Ningbo Fubang is expected to achieve a net profit of 50 million to 70 million yuan, with a staggering increase of 3,099.59% to 4,379.43% attributed to non-recurring gains from the sale of a stake in Ningbo Zhonghua Paper Industry [2] - Guangdong Mingzhu (SH600382) anticipates a net profit of approximately 166 million to 203 million yuan, reflecting a growth of 2,908.49% to 3,577.04% due to increased operational performance and non-operating gains [2] - Sino Medical (SH688108) expects a net profit of about 43 million to 50 million yuan, representing a year-on-year increase of 2,767% to 3,233% due to revenue growth and reduced asset impairment losses [2][3] Group 3: Significant Profit Decreases - Helitai (SZ002217) forecasts a net profit of 22 million to 33 million yuan, a decline of 97.83% to 98.55% compared to the previous year, primarily due to the absence of non-recurring gains from debt restructuring [4][5] - Longhong High-Tech (SH605008) and Yuancheng Co. (SZ002692) also expect significant profit declines of 97.88% to 98.41% and 96.8%, respectively, due to market conditions and strategic adjustments [6] - Vanke A projects a net loss of 82 billion yuan for 2025, up from a loss of approximately 49.48 billion yuan the previous year, attributed to decreased project settlement scales and increased impairment provisions [6][7] Group 4: Companies Exceeding Expectations - Among the 2,956 companies that disclosed forecasts, 147 companies exceeded institutional consensus estimates, including Zijin Mining (SH601899) with a projected net profit of 51 billion to 52 billion yuan, surpassing the consensus of approximately 49.95 billion yuan [8][9] - Industrial Fulian (SH601138) expects a net profit of 351 billion to 357 billion yuan, exceeding the consensus estimate of about 344.86 billion yuan [9] Group 5: Companies Falling Short of Expectations - Conversely, 858 companies reported forecasts below institutional consensus estimates, such as Muyuan Foods (SZ002714) with a projected net profit of 14.7 billion to 15.7 billion yuan, below the consensus of approximately 18.21 billion yuan [10] - Shenghong Technology (SZ300476) anticipates a net profit of 4.16 billion to 4.56 billion yuan, also falling short of the consensus estimate of about 5.03 billion yuan [10]

Investment Rating - The industry rating is maintained at "Overweight" [2] Core Insights - The vaccine industry is currently facing short-term performance pressure due to weak demand and structural oversupply, with many companies experiencing declines or losses in performance [1][7][8] - Despite the challenges, innovation and international expansion are ongoing, providing potential for medium to long-term growth [1][8] - The industry is transitioning from scale expansion to innovation-driven growth, with policy, demand, and technology as the three main driving factors for development [8][24][26] Summary by Sections Domestic and International Vaccine Dynamics - Kanghua Biotech has initiated Phase I clinical trials for its six-valent norovirus vaccine, which theoretically can prevent over 90% of norovirus infections [1] - Wantai Biopharma's bivalent HPV vaccine has successfully passed the WHO PQ periodic review [1] - Zhifei Biological's application for clinical trials of a freeze-dried inactivated vaccine for Japanese encephalitis has been accepted [1] Performance Forecasts - Chengda Bio expects a 59.34%-63.98% decrease in net profit for 2025 compared to the previous year [1] - CanSino anticipates a revenue increase of 22.88%-27.61% for 2025, with a turnaround in net profit [1] - Watson Bio forecasts a revenue of 2.4-2.43 billion yuan for 2025, a decline of approximately 14.9%-13.9% [1] - Other companies like Kangtai Bio and Wantai Bio also expect significant declines in net profit for 2025 [1] Market Performance - The vaccine sector saw a decline of 1.65% last week, with the overall pharmaceutical industry down 3.31% [2][5] - The vaccine sector has experienced a cumulative decline of 10.08% since the beginning of 2025 [5][13] Valuation Metrics - The vaccine sector's PE (ttm) is 92.01X, down 1.88X from the previous week, while the PB (lf) is 1.78X, down 0.04X [6] - The PE is at the 55.99% percentile since 2013, and the PB is at the 1.28% percentile since 2013 [6] Investment Recommendations - The vaccine industry is still under pressure, but companies are actively adjusting their pipeline strategies, focusing on technological innovation and multi-valent products [7][8] - Long-term prospects remain positive due to innovation and international market expansion, with a recommendation to focus on companies with strong R&D capabilities and differentiated product offerings, such as CanSino [8][26]

Core Viewpoint - Baillie Gifford continues to focus on technology and growth sectors, maintaining a global perspective despite a reduction in total assets held to $120 billion, down $15 billion from the previous quarter [1]. Holdings Overview - As of Q4 2025, Baillie Gifford holds a total of 265 companies with assets amounting to $120 billion, reflecting a decrease of $15 billion from Q3 [1]. Top Holdings - The firm remains heavily invested in global technology and consumer giants, with a notable emphasis on Latin American e-commerce platform MercadoLibre, and Nvidia leading the portfolio, indicating confidence in the long-term potential of AI infrastructure [4]. Top Buys - Significant increases in holdings include: - Axon Enterprise (AXON) with an additional investment of $860 million - Medline Inc (MDLN) with $437 million - Rocket Lab (RKLB) with $399 million - Google-A (GOOGL) with $373 million - Duolingo (DUOL) with $357 million - The firm shows strong interest in vertical technology sectors, particularly in safety technology and education [5][6]. Top Sells - The firm has reduced its positions in: - Datadog Inc (DDOG) by $1.01 billion - Cloudflare (NET) by $990 million - Shopify (SHOP) by $680 million - BioNTech SE (BNTX) by $630 million - Meta Platforms (META) by $590 million - This indicates a strategic retreat from cloud computing and vaccine-related companies, likely based on valuation and growth switching logic [7][8]. New Positions - New investments include: - Medline Inc (MDLN) with $437 million - United Therapeutics (UTHR) with $157 million - MongoDB (MDB) with $112 million - BillionToOne (BLLN) with $104 million - Silvergate Capital (SVM) with $35 million - The new positions reflect Baillie Gifford's exploration in emerging fields such as rare disease treatment and databases, showcasing a commitment to long-term tracking in technology and healthcare [9][10].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告由江蘇中慧元通生物科技股份有限公司（「本公司」或「中慧生物」，連同其 附屬公司，統稱「本集團」）自願刊發，以告知本公司股東及潛在投資者有關本集 團最新業務發展的資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，中國國家藥品監督管理局（「國家 藥監局」）已批准本集團針對所有年齡組別的三價流感病毒亞單位疫苗的新藥申 請。 截至本公告日期，該款疫苗成為中國首款且唯一一款獲批上市的全人群全劑量三 價流感病毒亞單位疫苗。該產品在傳統病毒裂解疫苗的基礎上進行重大升級，具 有保護全面、組分抗原純度高、不良反應風險低等優勢。 Ab&B Bio-Tech CO., LTD. JS 江蘇中慧元通生物科技股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2627） 自願性公告 我們是一家總部位於中國的疫苗公司，致力於創新疫苗及採用新技術方法的傳統 疫苗的研發、製造及商業化。我們密切追蹤傳染病的全球 ...